CAP TODAY Pathology/Laboratory Medicine/Laboratory Management
December 2019—nRichDX introduced its Revolution System, a high-yield sample prep platform designed to increase liquid biopsy–based test sensitivity by delivering more target input for molecular assays. The target yield increase is accomplished by combining the ability to process a range of sample volumes (3–50 mL) with recovery rates of 70–90 percent.
“After three years of development, we are very excited to introduce our Revolution System,” William Curtis, CEO of nRichDX, said in a company press release. “The data that we’ve developed in collaboration with early adopters like Dr. Greg Tsongalis of Dartmouth-Hitchcock Medical Center and Dr. Ryan Corcoran of Massachusetts General Hospital are highly compelling. We are confident that our Revolution System will advance the promise of precision medicine by enabling a significant increase in liquid biopsy–based test sensitivity.”